Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANCAD in Stable Angina Pectoris
NCT02294942Phase 3Completed
- Sponsor
- TSH Biopharm Corporation Limited
- Start
- Oct 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranolazine in stable angina pectoris (3 arms), sponsored by TSH Biopharm Corporation Limited. Primary endpoint: Exercise Treadmill Test duration at 12 weeks. Started Oct 2014; status: completed.
02
Drugs
ranolazine
03
Conditions
stable angina pectoris
Beyond the preview
Go deeper on NCT02294942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02294942.